EUVIMEDEUVIMED entdecken
Crossref

HER2 ‐positive grade 1 invasive carcinomas of the breast

Andrew H S Lee iD, Zsolt Hodi, Areeg Abbas, Ian O Ellis iD, Emad A Rakha iD

Histopathology · 2025

DOI: 10.1111/his.15315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Andrew H S Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Histopathology Department, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The American Society of Clinical Oncology and College of American Pathologists HER2‐guidelines recommend repeat testing for most grade 1 mammary carcinomas that are HER2‐positive in the core biopsy. This study aimed to assess the value of repeat HER2‐testing and the histological features of HER2‐positive grade 1 carcinomas. Methods and results A case‐series of HER2‐results of grade 1 carcinomas was conducted of patients with no pre‐operative systemic treatment over a 5‐year period. HER2‐positive carcinomas had histological review. Twelve HER2‐positive carcinomas were initially reported as grade 1. On review, two were reclassified as grade 2. The remaining 10 carcinomas represented 2% of the 508 grade 1 carcinomas. Eight HER2‐positive grade 1 carcinomas from other years were also studied. HER2‐positive carcinomas more often had marked nuclear pleomorphism (50 versus 6%) and were more often oestrogen receptor‐negative (17 versus 0.8%) and progesterone receptor‐negative (28 versus 8%) compared with HER2‐negative grade 1 carcinomas. Six carcinomas that were HER2 3+ in the core biopsy were also 3+ on repeat assessment. Five of seven carcinomas that were 2+ amplified in the core biopsy were also HER2‐positive in the excision.

Conclusions

HER2‐positive grade 1 carcinomas are uncommon, and more often have marked nuclear pleomorphism and lack oestrogen receptor and progesterone receptor expression compared with HER2‐negative grade 1 carcinomas. A HER2‐poitive result in the core biopsy was confirmed in 11 of 13 tumours that had repeat testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansFemaleMiddle AgedAgedAdultNeoplasm GradingAged, 80 and overImmunohistochemistryCarcinoma, Ductal, Breast

Stichwörter der Autor:innen

HER2breastcarcinomahistological gradein‐situ hybridisation

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Histopathology Department, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK.
  • Source Bioscience plc., Nottingham, UK.

ORCID-Profile: Andrew H S Lee, Ian O Ellis, Emad A Rakha

Zitieren

APA

Lee, A. H. S., Hodi, Z., Abbas, A., Ellis, I. O., & Rakha, E. A. (2025). HER2 ‐positive grade 1 invasive carcinomas of the breast. Histopathology. https://doi.org/10.1111/his.15315

Vancouver

Lee AHS, Hodi Z, Abbas A, Ellis IO, Rakha EA. HER2 ‐positive grade 1 invasive carcinomas of the breast. Histopathology. 2025. doi:10.1111/his.15315

BibTeX
@article{Lee2025,
  author = {Lee, Andrew H S and Hodi, Zsolt and Abbas, Areeg and Ellis, Ian O and Rakha, Emad A},
  title = {HER2 ‐positive grade 1 invasive carcinomas of the breast},
  journal = {Histopathology},
  year = {2025},
  doi = {10.1111/his.15315}
}
Kostenlos starten →